Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q1 2020 · 10-Q
Revenue$502.07M$502.07M+25.3% vs Q1 2019 Net Income$81.38M$81.38MN/M vs Q1 2019 EPS Diluted$0.44$0.44N/M vs Q1 2019 Operating Income$104,961,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Free Cash Flowderived-$55,748,000N/M Margins · derivedOperating margin20.9%+34.4 pt vs Q1 2019
Net margin16.2%+30.3 pt vs Q1 2019
ended Mar 31, 2020 · filed May 1, 2020 · 31 d after period end